# October 30, 2026 — scheduled focused research update [Home](../README.md) · [Latest](../LATEST.md) · [Milestones](../MILESTONES.md) All 32 active condition topics are represented below; the retained Sleep hub preserves history without duplicate monitoring. Each review is focused and incomplete. Full successful-check dates remain unchanged. Bulk registry retrieval is not complete clinical appraisal or a worldwide no-news determination. Source, publication, event, approval, verification and estimated completion dates remain distinct. Newly recovered older disclosures retain their original dates; historical baseline additions and repeated findings are excluded from alerts. Newly recorded informal timing and approval claims remain explicitly unconfirmed; existing original claims were revisited. ## Findings - **2026-10-29 — Sponsor study-amendment announcement and forecast:** [Taldefgrobep obesity trial adds a planned GLP-1 combination and later readout](../topics/04_muscle.md#note-2026-10-29-taldefgrobep-glp1-combo-h22027-forecast). - **2026-10-28 — New randomized active-controlled protocol:** [Knee stem-cell trial will compare clinical and structural outcomes separately](../topics/11_joint_preservation.md#note-2026-10-28-admsc-knee-active-control-registration). - **2026-09-18 — Informal timing report — unconfirmed:** [Unconfirmed timing: secondary reports place TG-C companion topline in December](../topics/11_joint_preservation.md#note-2026-09-18-tgc-december-timing-secondary-report). Excluded from the current-news feed. - **2026-10-29 — Dated sponsor conference/webinar announcement:** [ALLO-329 first autoimmune clinical update is scheduled for November 9](../topics/15_autoimmune.md#note-2026-10-29-allo329-resolution-first-data-schedule). - **2026-10-29 — Sponsor Phase 1 report; analgesic efficacy not established:** [Two non-opioid pain candidates add early human exposure and tolerability data](../topics/16_pain.md#note-2026-10-29-xen1701-xen1120-phase1-human-update). - **2026-10-29 — New Phase 4 protocol; nonrandomized historical comparator:** [STRIDE-HIP will compare suzetrigine with historical hip-fracture care](../topics/16_pain.md#note-2026-10-29-suzetrigine-stride-hip-registration). - **2026-10-30 — Registry timing-only update:** [HNK estimated start moves again without confirmed dosing](../topics/16_pain.md#note-2026-10-30-hnk-start-estimate-nov4). Excluded from the current-news feed. - **2026-10-30 — Sponsor-only randomized Phase 2a topline:** [Fexlamose COPD trial misses efficacy endpoints and reports more respiratory harms](../topics/26_allergy_airway.md#note-2026-10-30-fexlamose-copd-negative-topline). - **2026-10-28 — Phase 3 registry results:** [ARNASA posts mixed dose comparisons and distinct safety denominators](../topics/26_allergy_airway.md#note-2026-10-28-arnasa-astegolimab-registry-results). - **2026-10-28 — Open-label Phase 3 extension registry results:** [Peanut-patch extension reports challenge responses with attrition and ongoing-treatment limits](../topics/26_allergy_airway.md#note-2026-10-28-epopex-longterm-registry-results). - **2026-10-30 — New Phase 3 registration:** [AIRWARD registers a large COPD exacerbation trial](../topics/26_allergy_airway.md#note-2026-10-30-verducatib-airward-phase3-registration). - **2026-10-29 — New Phase 3 registry records; possible duplicate registration:** [Dust-mite immunotherapy registrations share one protocol identifier](../topics/26_allergy_airway.md#note-2026-10-29-hdm-mannan-allergoid-phase3-registration). - **2026-10-20 — Peer-reviewed prespecified descriptive process evaluation:** [ADAPT-Sepsis process study separates earlier stop advice from actual antibiotic reduction](../topics/27_infectious_disease.md#note-2026-10-20-adapt-sepsis-process-evaluation). - **2026-10-29 — New Phase 1 registration:** [Pancoronavirus vaccine enters a small first-human protocol](../topics/27_infectious_disease.md#note-2026-10-29-pancoronavirus-scaffold-vaccine-registration). - **2026-10-29 — Regulatory-event timing follow-up:** [EMA phage-workshop agenda updated; conclusions still unverified](../topics/27_infectious_disease.md#note-2026-10-29-ema-phage-workshop-window-review). Excluded from the current-news feed. - **2026-10-28 — Sponsor-only Phase 3 topline; randomized active comparison:** [Retatrutide outperforms Ozempic 2 mg in an 80-week diabetes trial](../topics/03_glp1.md#note-2026-10-28-retatrutide-transcend2-head-to-head). - **2026-10-28 — Peer-reviewed Phase 2 randomized publication and registry tables:** [Acmopatide publication adds dose-specific type 1 diabetes results](../topics/03_glp1.md#note-2026-10-28-acmopatide-type1-phase2-publication). - **2026-10-28 — New registered Phase 3 protocol; no results:** [ENLIGHTEN-10 registers eloralintide in diabetes with elevated cardiovascular risk](../topics/03_glp1.md#note-2026-10-28-eloralintide-enlighten10-protocol). - **2026-10-22 — Recovered new Phase 2 registry protocol; informal nickname is unconfirmed:** [An oral LY4086940 obesity study registers multiple doses and titration schedules](../topics/03_glp1.md#note-2026-10-22-ly4086940-oral-phase2-protocol). - **2026-10-28 — Sponsor development update; forecasts are not trial results:** [Viking updates maintenance and amylin-development timing](../topics/03_glp1.md#note-2026-10-28-viking-oct28-maintenance-milestones). - **2026-10-28 — New ClinicalTrials.gov results posting from a completed randomized Phase 2b study:** [AZD2693 FORTUNA does not improve its primary MASH histology endpoint](../topics/13_liver.md#note-2026-10-28-azd2693-fortuna-histology-results). - **2026-10-28 — New randomized Phase 3 registry results; safety-table limitations:** [Rifaximin SSD trial does not prevent first overt hepatic encephalopathy or death](../topics/13_liver.md#note-2026-10-28-rifaximin-ssd-redc3132-primary-null). - **2026-10-28 — New registered human protocols; no results:** [Two small MASLD trials register repurposed allergy and airway drugs](../topics/13_liver.md#note-2026-10-28-masld-rupatadine-roflumilast-protocols). - **2026-10-22 — Peer-reviewed randomized Phase 3 publication; sponsor supplies component and safety tables:** [VISIONARY adds two-year kidney-function and composite-event evidence](../topics/17_kidney.md#note-2026-10-22-sibeprenlimab-visionary-final-egfr). - **2026-10-29 — New randomized Phase 3 registry results; prior lack-of-efficacy termination:** [ARTEMIS results document lack of perioperative kidney benefit](../topics/17_kidney.md#note-2026-10-29-ravulizumab-artemis-null-results). - **2026-10-30 — New randomized Phase 1 registry results:** [A small dialysis trial reports empagliflozin feasibility rather than clinical benefit](../topics/17_kidney.md#note-2026-10-30-empagliflozin-dialysis-feasibility-results). - **2026-10-29 — New registered Phase 3 protocol; no results:** [EVERGREEN registers two JADE101 maintenance schedules for IgAN](../topics/17_kidney.md#note-2026-10-29-jade101-evergreen-phase3-protocol). - **2026-10-30 — New registered Phase 2 biomarker protocol; no results:** [A small trial will test tirzepatide against a proteomic brain-age measure](../topics/05_longevity.md#note-2026-10-30-tirzepatide-proteomic-brain-age-protocol). - **2026-10-30 — Registry status reconciliation; no new efficacy data:** [ELITE registry now records completion, with results still absent](../topics/05_longevity.md#note-2026-10-30-elite-actual-completion-no-results). Excluded from the current-news feed. - **2026-10-29 — New registered Phase 2 protocols; no results:** [Two trials will test single-dose lemborexant before neurosurgery](../topics/29_sleep_insomnia.md#note-2026-10-29-lemborexant-neurosurgery-protocols). - **2026-09-16 — Historical baseline; Historical baseline: observational analysis of self-selected online reviews:** [Patient-review analysis highlights tolerability concerns without estimating population rates](../topics/29_sleep_insomnia.md#note-2026-09-16-lemborexant-online-experience-baseline). Excluded from the current-news feed. - **2026-10-19 — Historical baseline; Historical context: original conference abstract for previously announced open-label extension:** [Original alixorexton extension abstract clarifies the dose-group limitations](../topics/31_sleep_hypersomnolence.md#note-2026-10-19-alixorexton-lte-original-abstract-baseline). Excluded from the current-news feed. - **2026-07-27 — Historical baseline; Historical baseline: small randomized human study:** [Small RLS study finds no added benefit from local vibration](../topics/33_sleep_restless_legs.md#note-2026-07-27-vibration-gabapentin-null-baseline). Excluded from the current-news feed. - **2026-10-28 — Public human diagnostic research protocols; no results:** [Paired Belgian studies register self-sampling research for gynecologic cancers](../topics/02_galleri.md#note-2026-10-28-margot-mysself-gynecologic-selfsampling-2026). Excluded from the current-news feed. - **2026-10-26 — Peer-reviewed screening-methods paper; not patient-outcome results:** [BRIDGES-NBS defines a genomic-screening condition list; patient benefit is still to be tested](../topics/28_genetic_screening.md#note-2026-10-26-bridges-nbs-condition-selection-paper-2026). Excluded from the current-news feed. - **2026-10-29 — Sponsor report of randomized Phase 2 conference results:** [Combi-TED reports survival signals, with an important statistical limit](../topics/14_cancer_vaccines.md#note-2026-10-29-combi-ted-final-phase2-report-2026). - **2026-10-29 — Dated sponsor development update; no new efficacy readout:** [Zanzalintinib gains a new renal-cancer readout window and lung-maintenance study](../topics/14_cancer_vaccines.md#note-2026-10-29-zanzalintinib-q3-development-milestones-2026). - **2026-10-30 — Trial-registry status disclosures; actual suspension dates unknown:** [Three vaccine registries describe operational suspensions, with no established safety hold](../topics/14_cancer_vaccines.md#note-2026-10-30-vaccine-operational-suspensions-recovered-2026). Excluded from the current-news feed. - **2026-10-29 — First public registry results from prematurely terminated randomized Phase 2 study:** [CabOSTar posts no analyzable efficacy results after recruitment failure](../topics/14_cancer_vaccines.md#note-2026-10-29-cabostar-first-results-recruitment-termination-2026). - **2026-10-29 — Sponsor announcement of scheduled scientific presentations:** [CTAD now has specific lecanemab and diranersen update sessions](../topics/08_alzheimers.md#note-2026-10-29-biogen-ctad2026-specific-sessions). - **2026-10-29 — Public randomized Phase 2 protocol; no results:** [A dose-ranging simenafil trial registers clinical Alzheimer outcomes](../topics/08_alzheimers.md#note-2026-10-29-simenafil-ad-phase2-registration-2026). - **2026-10-26 — Peer-reviewed randomized trial; abstract appraised, complete tables inaccessible:** [Mebufotenin Phase 2b publication adds uncertainty and safety detail](../topics/09_psychedelics.md#note-2026-10-26-bpl003-mebufotenin-jama-phase2b-2026). - **2026-10-30 — Trial-registry update plus dated sponsor material; no efficacy results:** [ELUMINA is now registered as completed; enrollment and timing sources differ](../topics/09_psychedelics.md#note-2026-10-30-vls01-elumina-completed-registry-2026). - **2026-10-23 — Informal statement — unconfirmed; original Reddit reproduction of inaccessible interview/report:** [Informal forecast: Rick Doblin is optimistic about MDMA approval in early 2027](../topics/09_psychedelics.md#note-2026-10-23-resilient-mdma-doblin-q12027-prediction-2026-10-23). - **2026-10-30 — Sponsor initiation announcement plus public Phase 2 protocol; no results:** [An orexin-2 agonist starts a depression study, with safety as the primary objective](../topics/10_ssri_antidepressants.md#note-2026-10-30-alks7290-mdd-phase2-initiation-2026). - **2026-10-07 — Peer-reviewed small open-label human study; primary abstract appraised:** [PIONEER optogenetic therapy reports partial light-sensitivity gains and ocular harms](../topics/18_hearing_vision.md#note-2026-10-07-pioneer-optogenetic-rp-publication-2026). - **2026-10-28 — Public Phase 2/3 protocol; no results:** [PERCEPT registers a sham-controlled optogenetic gene-therapy study for RP](../topics/18_hearing_vision.md#note-2026-10-28-rtx015-percept-phase23-registration-2026). - **2026-10-29 — Sponsor development announcement plus older original registry:** [Caliway announces enrollment in the second pivotal CBL-514 trial](../topics/06_localized_fat.md#note-2026-10-29-cbl514-supreme02-enrollment-announced). - **2026-10-30 — Dated sponsor availability clarification:** [CBL-514 remains unavailable commercially, Caliway clarifies](../topics/06_localized_fat.md#note-2026-10-30-cbl514-unauthorized-availability-clarification). - **2026-07-08 — Historical baseline; Historical baseline: published randomized Phase 2 protocol and current original registry:** [Baseline: TRIUMPH tests tesamorelin plus exercise for function in older adults with HIV](../topics/06_localized_fat.md#note-2026-07-08-tesamorelin-triumph-function-baseline). Excluded from the current-news feed. - **2026-10-30 — New randomized human-study registration; no results:** [PP405 registers a separate Phase 2 trial for female pattern hair loss](../topics/19_hair_loss.md#note-2026-10-30-pp405-female-awakening-phase2-registration). - **2026-10-28 — Peer-reviewed uncontrolled cohort; full article and adverse-event table appraised:** [IPL cohort describes reactions, with important reporting inconsistencies](../topics/20_skin_aging.md#note-2026-10-28-ipl-photoaging-cohort-reactions-inconsistencies). - **2026-10-29 — Peer-reviewed randomized study; primary abstract only:** [Burn-graft trial reports a scar/healing tradeoff](../topics/21_scars.md#note-2026-10-29-severe-burn-cea-asg-randomized-abstract). - **2026-10-29 — Registry recruitment and actual-start update; no results:** [RADIESSE China follow-up now records an actual start](../topics/22_facial_volume.md#note-2026-10-29-radiesse-china-actual-start-longterm-followup). - **2026-10-29 — Retrospectively registered randomized human protocol; no results:** [Crisaborole plus excimer light gains a registered vitiligo comparison](../topics/23_pigmentation.md#note-2026-10-29-crisaborole-excimer-facial-vitiligo-comparison). - **2026-10-29 — Peer-reviewed retrospective cohort; primary indexed abstract appraised:** [Enamel-reduction cohort adds caries observations, without an untreated comparison](../topics/25_dental.md#note-2026-10-29-aligner-interproximal-reduction-caries-cohort). ## Coverage by topic ### Whole-body MRI **Coverage: focused/incomplete.** 0 newly recorded entries. **Searches:** Read current full topic and core notebook files; deduplicated against605 saved events. Search overlap starts September5, through October30, with emphasis on material changes since October27.; Retrieved all pages of the ClinicalTrials.gov topic discovery query (2 records), then142 saved IDs and4 extra trial records in bulk; retrieval is distinct from clinical appraisal.; Focused primary paper, regulator, sponsor, conference and original informal-source searches for whole_body_mri; source/event dates retained. **Coverage and gaps:** focused_incomplete. HERCULES remains a stale April 2025 registry snapshot; enrollment invitation and estimated completion do not establish current recruitment or mortality benefit.; No complete repeat-round screening outcomes, harms or professional-guidance review.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged. **Informal sources and unresolved claims:** Targeted MRI screening outcome, Reddit and podcast searches mainly returned already saved review discussion and personal scan experiences. No distinct new source-grounded trial rumor was selected; full recordings were not comprehensively reviewed. **Sources checked:** - [Source 1](https://clinicaltrials.gov/study/NCT06212479) - [Source 2](https://link.springer.com/article/10.1007/s11606-026-10802-y) ### Galleri and organ-specific cancer screening **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** Read current full topic and core notebook files; deduplicated against605 saved events. Search overlap starts September5, through October30, with emphasis on material changes since October27.; Retrieved all pages of the ClinicalTrials.gov topic discovery query (187 records), then142 saved IDs and4 extra trial records in bulk; retrieval is distinct from clinical appraisal.; Focused primary paper, regulator, sponsor, conference and original informal-source searches for galleri; source/event dates retained. **Coverage and gaps:** focused_incomplete. Noncontrast DWIBS breast-MRI paper DOI10.3390/cancers18213417 again returned MDPI429; no performance values imported.; No new full randomized MCED mortality/overdiagnosis analysis; new self-sampling case-control programs do not establish those outcomes.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged. **Informal sources and unresolved claims:** GRAIL current news index contains an October27 investor-conference notice and the prior advisory-vote release, not a final FDA approval. Approval predictions were not corroborated; no distinct new attributable rumor selected. **Sources checked:** - [Source 1](https://investors.grail.com/news-events/news-releases) - [Source 2](https://clinicaltrials.gov/study/NCT07902388) - [Source 3](https://clinicaltrials.gov/study/NCT07902375) ### GLP-1 and related metabolic therapies **Coverage: focused/incomplete.** 5 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (obesity OR overweight OR GLP-1) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-30]; total: 1097; retrieved: 1097; pages: 11; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeRuPg1L3vIFvHRzo5F0yyQYM4BT74; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQvv87L3vIFvHRzo5F0iiZa88FTL4; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQuf00JXvIFvHRzo5F0CuQb84NS74; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeTsPk1K3vIFvHRzo5F0y2ZYcAMRr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeTu_49L3vIFvHRzo5F0imRbscDQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSsPQ1L3vIFvHRzo5F1y-YacEMQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSvvk8LXvIFvHRzo5F0CmXbcMDS74; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSuf89K3vIFvHRzo5F0iyTacYGSr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzabvv0_L3vIFvHRzo5F0iaQb8YMTb4; https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzabuPU4JXvIFvHRzo5F0iiQbs4BR74; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 October 28 retatrutide TRANSCEND T2D2 Ozempic 2 mg results Lilly; October 2026 eloralintide EloraTZP AMPLIFY2 recruitment dose; October 2026 acmopatide CT868 type 1 diabetes Diabetes Care; Viking October 28 2026 VK2735 VK3019 maintenance results; site:reddit.com/r/GLP1ResearchTalk October 2026 October 28 29 30 trial **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; TRANSCEND-T2D-2 full paper, visit-level curves, confidence intervals, actual arm denominators, treatment-regimen estimand and complete serious-event tables are not yet supplied by the topline release.; AMPLIFY-2 sponsor page still says enrolling while its last October 19 registry record remains not yet recruiting; AMPLIFY-1 sponsor page says not yet enrolling. Numeric EloraTZP doses and complete titration remain undisclosed; actual first dosing is unverified.; New SUN0864/PAL119 protocols and JOULE-3 mechanistic protocol were discovered but not fully appraised; JOULE-3 contains an apparent future actual-start date requiring reconciliation. **Informal sources and unresolved claims:** Re-read the original ENLIGHTEN-6 and SOLIS-1 Reddit threads; individual experience remains unconfirmed, with no new corroboration or status change. Recovered the original LY4086940 “oral reta” post and traced its trial link; the nickname does not establish compound equivalence. Targeted new Reddit and sponsor-call searches were selective, not a full transcript census. **Sources checked:** - [Source 1](https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more) - [Source 2](https://clinicaltrials.gov/study/NCT06260722) - [Source 3](https://doi.org/10.2337/dc26-1059) - [Source 4](https://pubmed.ncbi.nlm.nih.gov/42949535/) - [Source 5](https://clinicaltrials.gov/study/NCT06062069) - [Source 6](https://clinicaltrials.gov/study/NCT07900633) - [Source 7](https://clinicaltrials.gov/study/NCT07890376) - [Source 8](https://www.reddit.com/r/FoundayoPill/comments/1xd3fw7/lillys_oral_reta_to_begin_phase_2_clinical_trial/) - [Source 9](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update) ### Muscle building and preservation **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** 28 updated registry-discovery records retrieved plus all saved trial IDs; targeted sponsor/publication and original informal-source follow-up. **Coverage and gaps:** focused_incomplete. Amended taldefgrobep partner/dose and actual combination first dosing remain unverified. Full COURAGE manuscript, BELIEVE withdrawal tables and complete worldwide muscle appraisal remain gaps. **Informal sources and unresolved claims:** The enobosarm Cantor Phase 3 planning claim remains unconfirmed; no original new start/protocol corroboration. Original complete audio remains unreviewed. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28myostatin+OR+bimagrumab+OR+enobosarm+OR+%22muscle+preservation%22+OR+deramiocel%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&countTotal=true) - [Source 2](https://ir.verupharma.com/news-events) - [Source 3](https://ir.scholarrock.com/news-releases) - [Source 4](https://investor.regeneron.com/news-releases) - [Source 5](https://biohaven.gcs-web.com/news-releases/news-release-details/biohaven-reports-recent-business-developments-and-third-quarter) ### Longevity and healthspan trials **Coverage: focused/incomplete.** 2 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (longevity OR healthspan OR metformin aging OR rapamycin aging OR senolytic) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-30]; total: 81; retrieved: 81; pages: 1; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28longevity+OR+healthspan+OR+metformin+aging+OR+rapamycin+aging+OR+senolytic%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 metformin rapamycin TAME REPROGRAM healthspan human trial results; site:reddit.com/r/longevity October 2026 rapamycin trial; PEARL 24 month Vitaei primary citation **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; AFAR TAME page again returned 404; funded launch and actual first dosing cannot be refreshed. No new verified TAME efficacy result.; ELITE has no posted results despite now completed status. MAVRIC/other saved geroscience dates are not treated as actual starts or readouts.; Proteomic age and inflammatory-age measures are not validated replacements for demonstrated function, disease-free survival or longevity. **Informal sources and unresolved claims:** Re-read the original Vitaei PEARL 24-month claim; no matching original 24-month clinical report was verified, and the offered citation remains unrelated as previously documented. Targeted rapamycin/metformin Reddit searches did not supply a new selected, attributable human-trial update. **Sources checked:** - [Source 1](https://clinicaltrials.gov/study/NCT07906041) - [Source 2](https://clinicaltrials.gov/study/NCT07475546) ### Localized fat removal and cellulite **Coverage: focused/incomplete.** 3 newly recorded entries. **Searches:** type: fresh registry discovery and all saved NCT refresh; window: 2026-09-05 through 2026-10-30; retrieved: 161; namedIds: NCT00675506; NCT02196831; NCT03375788; NCT04867434; NCT05445557; NCT05632926; NCT05736107; NCT06256445; NCT06303570; NCT07140939; NCT07481734; NCT07608757; NCT07608770; NCT07802431; NCT07862920; NCT07864246; NCT07880301; errors: ; note: All pages retrieved; selective appraisal only, with older incidental matches excluded.; type: fresh primary MED indexed-paper discovery; window: 2026-09-05 through 2026-10-30; retrieved: 41; note: Core abstracts retrieved, selected full primary sources appraised.; type: primary sponsor/regulator and original informal follow-up; description: Targeted original Reddit and indexed talk/podcast searches sampled; an anonymous October24 tesamorelin reaction account has unverified product identity, self-experimental co-exposures and no adjudicated causality. It does not establish a new formal-trial safety signal. No selected new development rumor; marketplace sourcing claims remain separate from authorized access. **Coverage and gaps:** focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; SUPREME-02 actual first-enrollment/dose day and registry reconciliation remain unverified.; No new matched RZL012 efficacy/China filing or tesamorelin new-indication result verified; all devices/cellulite comparative evidence not appraised. New 30-woman PLLA/CaHA cellulite registry NCT07908069 describes a study completed2025 with no results; do not call it a newly started2026 trial. **Informal sources and unresolved claims:** Targeted original Reddit and indexed talk/podcast searches sampled; an anonymous October24 tesamorelin reaction account has unverified product identity, self-experimental co-exposures and no adjudicated causality. It does not establish a new formal-trial safety signal. No selected new development rumor; marketplace sourcing claims remain separate from authorized access. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28localized+fat+OR+cellulite+OR+tesamorelin+OR+CBL-514+OR+RZL-012+OR+lipedema%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true) - [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28localized+fat+OR+cellulite+OR+tesamorelin+OR+CBL-514+OR+RZL-012+OR+lipedema%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSv_86KXvIFvHRzo5F1S-TacIAS74) - [Source 3](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT00675506%2CNCT02196831%2CNCT03375788%2CNCT04867434%2CNCT05445557%2CNCT05632926%2CNCT05736107%2CNCT06256445%2CNCT06303570%2CNCT07140939%2CNCT07481734%2CNCT07608757%2CNCT07608770%2CNCT07802431%2CNCT07862920%2CNCT07864246%2CNCT07880301&pageSize=100&format=json) - [Source 4](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22localized+fat%22+OR+%22cellulite%22+OR+%22tesamorelin%22+OR+%22CBL-514%22+OR+%22RZL-012%22+OR+%22lipedema%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-30%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000) - [Source 5](https://www.caliwaybiopharma.com/en/news/2026/) - [Source 6](https://www.reddit.com/r/Biohackers/comments/1xehn9e/anaphylaxis_after_7_months_of_tesamorelin_my/) - [Source 7](https://www.caliwaybiopharma.com/en/news-detail/CBL-514-supreme-02-phase-3-trial-enrollment-initiated-ENG/) - [Source 8](https://clinicaltrials.gov/study/NCT07526974) - [Source 9](https://clinicaltrials.gov/study/NCT07140939) - [Source 10](https://www.caliwaybiopharma.com/en/news-detail/Caliway--clarification-of-misleading-cbl-514-sales-information-ENG/) - [Source 11](https://clinicaltrials.gov/study/NCT06554717) - [Source 12](https://pmc.ncbi.nlm.nih.gov/articles/PMC13347827/) - [Source 13](https://doi.org/10.1136/bmjopen-2026-120740) ### Broad cardiovascular prevention, lipids and screening **Coverage: focused/incomplete.** 0 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (hypercholesterolemia OR dyslipidemia OR lipoprotein OR atherosclerosis OR coronary artery calcium OR CCTA) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-30]; total: 623; retrieved: 623; pages: 7; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28hypercholesterolemia+OR+dyslipidemia+OR+lipoprotein+OR+atherosclerosis+OR+coronary+artery+calcium+OR+CCTA%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://clinicaltrials.gov/api/v2/studies?query.term=%28hypercholesterolemia+OR+dyslipidemia+OR+lipoprotein+OR+atherosclerosis+OR+coronary+artery+calcium+OR+CCTA%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQv_w_K3vIFvHRzo5F0yyTYcMNSr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28hypercholesterolemia+OR+dyslipidemia+OR+lipoprotein+OR+atherosclerosis+OR+coronary+artery+calcium+OR+CCTA%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQuP8-KXvIFvHRzo5F1yiSaM4NQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28hypercholesterolemia+OR+dyslipidemia+OR+lipoprotein+OR+atherosclerosis+OR+coronary+artery+calcium+OR+CCTA%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeTu_49L3vIFvHRzo5F0i-RasEEQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28hypercholesterolemia+OR+dyslipidemia+OR+lipoprotein+OR+atherosclerosis+OR+coronary+artery+calcium+OR+CCTA%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSvvk8LXvIFvHRzo5F0yaZaMAFQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28hypercholesterolemia+OR+dyslipidemia+OR+lipoprotein+OR+atherosclerosis+OR+coronary+artery+calcium+OR+CCTA%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzabvvU1K3vIFvHRzo5F0i-UbcEMSL4; https://clinicaltrials.gov/api/v2/studies?query.term=%28hypercholesterolemia+OR+dyslipidemia+OR+lipoprotein+OR+atherosclerosis+OR+coronary+artery+calcium+OR+CCTA%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaasfw-LXvIFvHRzo5F0yqZYc8NTb4; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 cardiovascular lipid lowering VERVE enlicitide pelacarsen trial results; October 2026 ARTEMIS ravulizumab cardiac surgery results; site:reddit.com October 2026 VERVE trial **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; Named lipid/base-editing/outcomes records were refreshed, but new broad-CV safety/outcomes evidence outside the selected searches was not exhaustively appraised.; ARTEMIS is recorded under kidney and cross-linked here; it does not establish a preventive lipid/CV indication. Enrollment of high-CV-risk people in ENLIGHTEN-10 does not make it a cardiovascular outcomes trial. **Informal sources and unresolved claims:** Targeted original Reddit searches for VERVE and lipid trials were reviewed. No new independently appraisable informal claim was selected; full podcast/talk transcripts and all patient-community discussion remain unsearched. **Sources checked:** - [Source 1](https://clinicaltrials.gov/study/NCT05746559) - [Source 2](https://clinicaltrials.gov/study/NCT07900633) ### Alzheimer's screening and therapies **Coverage: focused/incomplete.** 2 newly recorded entries. **Searches:** Read current full topic and core notebook files; deduplicated against605 saved events. Search overlap starts September5, through October30, with emphasis on material changes since October27.; Retrieved all pages of the ClinicalTrials.gov topic discovery query (102 records), then142 saved IDs and4 extra trial records in bulk; retrieval is distinct from clinical appraisal.; Focused primary paper, regulator, sponsor, conference and original informal-source searches for alzheimers; source/event dates retained. **Coverage and gaps:** focused_incomplete. CTAD talks remain future; no new CELIA/Clarity/LEADER outcomes inferred from the schedule.; Full antiamyloid safety/label/assay-clearance inventory and all worldwide registries remain incomplete.; Full Longo and Davidson podcast refresh not completed; original public material and existing registry context do not confirm prevention benefit.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged. **Informal sources and unresolved claims:** Longo trial-planning/funding comments and Davidson/obicetrapib prevention hypothesis remain unconfirmed as clinical-benefit claims. SPINOZA recruitment was already recorded; a new check does not make the biomarker study evidence of prevention. **Sources checked:** - [Source 1](https://biogen.gcs-web.com/news-releases/news-release-details/biogen-present-new-data-across-alzheimers-disease-portfolio-ctad) - [Source 2](https://clinicaltrials.gov/study/NCT07905352) - [Source 3](https://clinicaltrials.gov/study/NCT07794670) ### Psilocybin and related therapies **Coverage: focused/incomplete.** 3 newly recorded entries. **Searches:** Read current full topic and core notebook files; deduplicated against605 saved events. Search overlap starts September5, through October30, with emphasis on material changes since October27.; Retrieved all pages of the ClinicalTrials.gov topic discovery query (14 records), then142 saved IDs and4 extra trial records in bulk; retrieval is distinct from clinical appraisal.; Focused primary paper, regulator, sponsor, conference and original informal-source searches for psychedelics; source/event dates retained. **Coverage and gaps:** focused_incomplete. JAMA full mebufotenin tables/supplements were inaccessible; trial abstract and publisher summary checked. The latter is an editorial summary, not a replacement for primary tables.; ELUMINA actual142 versus prior sponsor156 enrollment difference remains unexplained; no result table posted.; Original Doblin interview/event recording and Robin Carhart-Harris X post were inaccessible. Podcast October20 original show notes opened, but no complete audio/timestamp review.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged. **Informal sources and unresolved claims:** Read original October26 r/shroomstocks discussion and October23 Doblin-report thread, plus October20 Psychedelic Alpha podcast show notes. The newly appraised Doblin Q12027 approval forecast is labeled secondhand/unconfirmed; unattributed stock-price and simultaneous-approval inferences are not independent confirmation. Full audio and original newspaper/X sources remain inaccessible. **Sources checked:** - [Source 1](https://jamanetwork.com/journals/jama/article-abstract/2855796) - [Source 2](https://clinicaltrials.gov/study/NCT06524830) - [Source 3](https://www.reddit.com/r/shroomstocks/comments/1xdpxki/exclusive_mdmaassisted_therapy_could_get_fda/) ### Mental-health treatments, SSRIs and newer antidepressants **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** Read current full topic and core notebook files; deduplicated against605 saved events. Search overlap starts September5, through October30, with emphasis on material changes since October27.; Retrieved all pages of the ClinicalTrials.gov topic discovery query (813 records), then142 saved IDs and4 extra trial records in bulk; retrieval is distinct from clinical appraisal.; Focused primary paper, regulator, sponsor, conference and original informal-source searches for ssri_antidepressants; source/event dates retained. **Coverage and gaps:** focused_incomplete. No exhaustive global medication, relapse, mood-switching or safety-label appraisal. ALKS numerical dose is not public.; iTBS article PMID42581396 first online August12 and lumateperone safety paper PMID42455478 first online July15 are older leads; October issue dates are not new results.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged. **Informal sources and unresolved claims:** Patient anecdotes and older antidepressant safety reposts did not establish a new specific trial or regulatory rumor. The formal ALKS announcement is separate from optimistic claims about broad mood or cognitive enhancement; complete podcast/Q&A coverage remains incomplete. **Sources checked:** - [Source 1](https://alkermes.gcs-web.com/news-releases/news-release-details/alkermes-expands-alks-7290-development-program-initiation-phase) - [Source 2](https://clinicaltrials.gov/study/NCT07901179) ### Bone health, joint preservation and cartilage repair **Coverage: focused/incomplete.** 2 newly recorded entries. **Searches:** 148 registry-discovery records across both pages, all saved IDs, named TG-C/lorecivivint/TST002 programs and new cell-therapy protocol appraised. **Coverage and gaps:** focused_incomplete. Senolytic osteoporosis NCT06018467 still has no original API results despite aggregator leads. Original TG-C December-delay statement remains missing; no companion outcome verified. Complete worldwide bone/fracture/cartilage appraisal unfinished. **Informal sources and unresolved claims:** Recovered E-Daily September18 and CBC August24 timing reports are labeled unconfirmed, with missing original recording and shared-source limitations. **Sources checked:** - [Source 1](https://clinicaltrials.gov/study/NCT07901790) - [Source 2](https://en.edaily.co.kr/news/eda202609185771/) - [Source 3](https://cbcglobe.com/en/articles/2026/08/24/kolon-tissuegene-s-second-u-s-phase-3-trial-topline-for-tg-c-6b983b13) - [Source 4](https://clinicaltrials.gov/study/NCT03203330) - [Source 5](https://clinicaltrials.gov/api/v2/studies?query.term=%28osteoporosis+OR+%22cartilage+repair%22+OR+lorecivivint+OR+%22TG-C%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&countTotal=true) ### Liver health and noninvasive assessment **Coverage: focused/incomplete.** 3 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (MASH OR NASH OR liver fibrosis OR fatty liver OR noninvasive liver) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-30]; total: 298; retrieved: 298; pages: 3; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28MASH+OR+NASH+OR+liver+fibrosis+OR+fatty+liver+OR+noninvasive+liver%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://clinicaltrials.gov/api/v2/studies?query.term=%28MASH+OR+NASH+OR+liver+fibrosis+OR+fatty+liver+OR+noninvasive+liver%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeTsPk1K3vIFvHRzo5F0CiSb8YDRr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28MASH+OR+NASH+OR+liver+fibrosis+OR+fatty+liver+OR+noninvasive+liver%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSuf89K3vIFvHRzo5F1yiVaccBQg; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 MASH MASLD liver trial results AZD2693 FORTUNA; October 2026 rifaximin SSD RED C3132 results; Madrigal October 27 2026 AASLD Liver Meeting abstracts; site:reddit.com October 2026 MASH trial results **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; Full AZD2693 study-report/publication reconciliation remains incomplete; the October 28 date identifies ClinicalTrials.gov posting, not necessarily the first public disclosure anywhere.; RED-C-3132 safety fields are internally problematic/incomplete and require clarification before comparative-safety conclusions.; Original AASLD November 5–9 full abstracts and all announced analyses were not comprehensively appraised; scheduled presentations are not delivered results. September CHMP MASH-procedure outcome remains unresolved. **Informal sources and unresolved claims:** Re-read the original Reddit post about the September CHMP Wegovy MASH agenda omission and current EMA EPAR. The original inference remains unresolved; absence from the retrieved indication summary does not establish rejection. Other MASH rumor searches were selective. **Sources checked:** - [Source 1](https://clinicaltrials.gov/study/NCT05809934) - [Source 2](https://clinicaltrials.gov/study/NCT05297448) - [Source 3](https://clinicaltrials.gov/study/NCT07900100) - [Source 4](https://clinicaltrials.gov/study/NCT07900087) ### Cancer treatment, vaccines and recurrence prevention **Coverage: focused/incomplete.** 4 newly recorded entries. **Searches:** Read current full topic and core notebook files; deduplicated against605 saved events. Search overlap starts September5, through October30, with emphasis on material changes since October27.; Retrieved all pages of the ClinicalTrials.gov topic discovery query (191 records), then142 saved IDs and4 extra trial records in bulk; retrieval is distinct from clinical appraisal.; Focused primary paper, regulator, sponsor, conference and original informal-source searches for cancer_vaccines; source/event dates retained. **Coverage and gaps:** focused_incomplete. INTerpath journal full paper and complete safety/OS supplements remain unverified; presentation and October22 efficacy were already saved.; Combi-TED full conference tables and between-arm confirmatory statistics remain unavailable; sponsor final report used.; Vaccine actual suspension dates and restart dates are unknown; no regulator clinical-hold inference. Full worldwide kinase/ADC/cellular/radiopharmaceutical discovery remains incomplete.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged. **Informal sources and unresolved claims:** REGAL imminent-event80 community speculation remains unconfirmed; the sponsor news index is dynamically incomplete. New operational-pause records do not corroborate an efficacy or toxicity rumor. No distinct new oncology rumor selected. **Sources checked:** - [Source 1](https://ml-eu.globenewswire.com/Resource/Download/eeb74ec1-6eae-419c-a7c7-273756e2c623) - [Source 2](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-third-quarter-2026-financial-results-and) - [Source 3](https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications) ### Autoimmune disease and immune reset **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** 41 discovery records and saved program refresh, original Allogene announcement, Immutep quarterly report, BMS pause/hold follow-up and informal-source leads. **Coverage and gaps:** focused_incomplete. No primary confirmation of zola-cel voluntary-pause end. Allogene first clinical data are scheduled, not released. IMP761 ACR poster and complete worldwide autoimmune coverage remain to appraise. **Informal sources and unresolved claims:** Mount Sinai IBD CAR-T planning remains unconfirmed; no original new dosing announcement recovered. Patient/stock discussions do not independently confirm efficacy or restart. **Sources checked:** - [Source 1](https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-november-investor-events) - [Source 2](https://clinicaltrials.gov/study/NCT07085104) - [Source 3](https://clinicaltrials.gov/api/v2/studies?query.term=%28%22CAR+T%22+OR+%22immune+reset%22+OR+fenebrutinib+OR+%22Treg%22%29+AND+%28lupus+OR+myositis+OR+%22multiple+sclerosis%22+OR+%22rheumatoid+arthritis%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&countTotal=true) - [Source 4](https://www.immutep.com/immutep-quarterly-activities-report-q1-fy27/) - [Source 5](https://mssm.cloud-cme.com/course/courseoverview?EID=49026&P=0) ### Non-opioid pain treatments **Coverage: focused/incomplete.** 3 newly recorded entries. **Searches:** 76 updated discovery records plus saved non-opioid programs; Xenon original IASP report/abstract, new STRIDE-HIP and HNK records appraised. **Coverage and gaps:** focused_incomplete. Original Xenon poster PDFs were inaccessible, cohort denominators and full safety tables remain incomplete. Patient analgesic efficacy is not established by healthy-volunteer exposure or animal pain experiments. Worldwide and full transcript appraisal incomplete. **Informal sources and unresolved claims:** No distinct original new development rumor selected; broader Reddit/podcast coverage incomplete. HNK shifted start remains a registry estimate, not confirmed dosing. **Sources checked:** - [Source 1](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-announces-positive-phase-1-and-new-preclinical-data-iasp) - [Source 2](https://xenon-pharma.com/pdfs/iasp-26-gilbert-xen1701.pdf) - [Source 3](https://xenon-pharma.com/pdfs/iasp-26-gilbert-xen1120.pdf) - [Source 4](https://clinicaltrials.gov/study/NCT07905404) - [Source 5](https://clinicaltrials.gov/study/NCT07504601) - [Source 6](https://clinicaltrials.gov/api/v2/studies?query.term=%28suzetrigine+OR+%22VX-993%22+OR+onzotrigine+OR+%22LTG321%22+OR+%22non-opioid%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&countTotal=true) ### Kidney preservation and earlier detection **Coverage: focused/incomplete.** 4 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (chronic kidney disease OR IgA nephropathy OR C3 glomerulopathy OR kidney preservation) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-30]; total: 487; retrieved: 487; pages: 5; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28chronic+kidney+disease+OR+IgA+nephropathy+OR+C3+glomerulopathy+OR+kidney+preservation%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://clinicaltrials.gov/api/v2/studies?query.term=%28chronic+kidney+disease+OR+IgA+nephropathy+OR+C3+glomerulopathy+OR+kidney+preservation%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQv_w_K3vIFvHRzo5F1S-RYccFSL4; https://clinicaltrials.gov/api/v2/studies?query.term=%28chronic+kidney+disease+OR+IgA+nephropathy+OR+C3+glomerulopathy+OR+kidney+preservation%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeTsPk1K3vIFvHRzo5F0i-YYcUGTL4; https://clinicaltrials.gov/api/v2/studies?query.term=%28chronic+kidney+disease+OR+IgA+nephropathy+OR+C3+glomerulopathy+OR+kidney+preservation%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSv_86KXvIFvHRzo5F0yiUbsUARr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28chronic+kidney+disease+OR+IgA+nephropathy+OR+C3+glomerulopathy+OR+kidney+preservation%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzabvfw6JXvIFvHRzo5F0C2TaMYCSb4; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 VISIONARY final sibeprenlimab eGFR NEJM; October 2026 IgA nephropathy JADE101 EVERGREEN trial; October 2026 ASN Kidney Week pegcetacoplan VALIANT results; site:reddit.com IgAN October 2026 trial kidney **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; Full VISIONARY article/supplement and detailed discontinuation/composite adjudication tables were not recovered; abstract and original sponsor component/safety tables were appraised.; ASN pegcetacoplan scheduled windows were revisited through targeted sources, but no additional original poster table was recovered or presumed delivered.; New crovalimab aHUS, transplant Treg/clazakizumab and other registry results were discovered but not fully appraised; complete kidney indications and safety coverage remain incomplete. **Informal sources and unresolved claims:** Targeted original IgAN/kidney Reddit searches yielded individual treatment experiences and reposts rather than a newly selected development rumor. They were not promoted to trial evidence; complete podcast/talk transcript coverage remains incomplete. **Sources checked:** - [Source 1](https://pubmed.ncbi.nlm.nih.gov/42911185/) - [Source 2](https://www.otsuka-us.com/Otsuka-Presents-Final-Phase-3-VISIONARY-Results) - [Source 3](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-voyxact) - [Source 4](https://clinicaltrials.gov/study/NCT05248646) - [Source 5](https://clinicaltrials.gov/study/NCT05746559) - [Source 6](https://clinicaltrials.gov/study/NCT05614115) - [Source 7](https://clinicaltrials.gov/study/NCT07902817) - [Source 8](https://jadebiosciences.com/pipeline/jade101/) - [Source 9](https://jadebiosciences.com/press-release/jade-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate-update/) ### Hearing and vision preservation/restoration **Coverage: focused/incomplete.** 2 newly recorded entries. **Searches:** Read current full topic and core notebook files; deduplicated against605 saved events. Search overlap starts September5, through October30, with emphasis on material changes since October27.; Retrieved all pages of the ClinicalTrials.gov topic discovery query (725 records), then142 saved IDs and4 extra trial records in bulk; retrieval is distinct from clinical appraisal.; Focused primary paper, regulator, sponsor, conference and original informal-source searches for hearing_vision; source/event dates retained. **Coverage and gaps:** focused_incomplete. PIONEER full NEJM article/supplement inaccessible; primary PubMed abstract appraised. Patient-level duration and complete functional-task tables remain gaps.; AC102 sponsor tinnitus page timed out; current trial registry remains January16 active-not-recruiting with elapsed estimates. No formal2027tinnitus/Phase3 launch verified.; Complete BEST1 and MCO010 acquired-GA tables and worldwide acquired sensory-loss program appraisal remain incomplete.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged. **Informal sources and unresolved claims:** Original AC102 purported-email thread remains a conditional2027development claim. Gerbil tinnitus stories do not confirm human efficacy. No formal sponsor/registry confirmation of the new tinnitus/Phase3 schedule was verified; do not repeat an unchanged alert. **Sources checked:** - [Source 1](https://pubmed.ncbi.nlm.nih.gov/42842903/) - [Source 2](https://clinicaltrials.gov/study/NCT07901751) - [Source 3](https://clinicaltrials.gov/study/NCT05776459) ### Hair loss, restoration and graying **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** type: fresh registry discovery and all saved NCT refresh; window: 2026-09-05 through 2026-10-30; retrieved: 162; namedIds: NCT02275351; NCT03570749; NCT03811912; NCT03899259; NCT05723198; NCT05910450; NCT05914805; NCT06018428; NCT06393452; NCT06692465; NCT06724614; NCT06972264; NCT07079657; NCT07317544; NCT07340697; NCT07484061; NCT07810504; NCT07819435; NCT07839494; NCT07862374; NCT07863856; NCT07869199; errors: ; note: All pages retrieved; selective appraisal only, with older incidental matches excluded.; type: fresh primary MED indexed-paper discovery; window: 2026-09-05 through 2026-10-30; retrieved: 248; note: Core abstracts retrieved, selected full primary sources appraised.; type: primary sponsor/regulator and original informal follow-up; description: Original BQ002 and clascoterone rumor posts and primary sites revisited; both existing claims remain unconfirmed with no repeated alert. Indexed PP405 commentary repeats grey-market self-experiments and older sponsor claims; those are not controlled formulation-equivalent outcomes. The October26 DermSurgery Digest notes were read, but full audio/transcript and transplant-neogenesis primary paper remain unappraised. **Coverage and gaps:** focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; October29 oral/topical minoxidil cohort PMID42957001 and October28 long-term baricitinib AA report PMID42949409 surfaced without accessible quantitative text; title-only claims are not appraised efficacy.; BQ002 candidate-specific human start and clascoterone launch dates remain unconfirmed. No new general hair-loss FDA approval verified. **Informal sources and unresolved claims:** Original BQ002 and clascoterone rumor posts and primary sites revisited; both existing claims remain unconfirmed with no repeated alert. Indexed PP405 commentary repeats grey-market self-experiments and older sponsor claims; those are not controlled formulation-equivalent outcomes. The October26 DermSurgery Digest notes were read, but full audio/transcript and transplant-neogenesis primary paper remain unappraised. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28alopecia+OR+hair+loss+OR+hair+graying%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true) - [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28alopecia+OR+hair+loss+OR+hair+graying%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSv_86KXvIFvHRzo5F0yqXaMIDRr4) - [Source 3](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT02275351%2CNCT03570749%2CNCT03811912%2CNCT03899259%2CNCT05723198%2CNCT05910450%2CNCT05914805%2CNCT06018428%2CNCT06393452%2CNCT06692465%2CNCT06724614%2CNCT06972264%2CNCT07079657%2CNCT07317544%2CNCT07340697%2CNCT07484061%2CNCT07810504%2CNCT07819435%2CNCT07839494%2CNCT07862374%2CNCT07863856%2CNCT07869199&pageSize=100&format=json) - [Source 4](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22alopecia%22+OR+%22hair+loss%22+OR+%22hair+graying%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-30%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000) - [Source 5](https://www.bioq.com/) - [Source 6](https://www.cosmohealthconfidence.com/news/64300770-h1-2026) - [Source 7](https://pubmed.ncbi.nlm.nih.gov/42957001/) - [Source 8](https://pubmed.ncbi.nlm.nih.gov/42949409/) - [Source 9](https://dermsurgerydigest.buzzsprout.com/2364656/episodes/20021371-october-2026-spotlight-cosmetic-and-general-dermatology) - [Source 10](https://clinicaltrials.gov/study/NCT07907783) ### Skin aging, laxity and regeneration **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** type: fresh registry discovery and all saved NCT refresh; window: 2026-09-05 through 2026-10-30; retrieved: 134; namedIds: NCT04717934; NCT05248867; NCT06477172; NCT06724900; NCT07224880; NCT07661004; NCT07790237; NCT07849205; NCT07849556; NCT07853027; NCT07866131; NCT07870694; NCT07880756; NCT07881926; errors: ; note: All pages retrieved; selective appraisal only, with older incidental matches excluded.; type: fresh primary MED indexed-paper discovery; window: 2026-09-05 through 2026-10-30; retrieved: 104; note: Core abstracts retrieved, selected full primary sources appraised.; type: primary sponsor/regulator and original informal follow-up; description: Sampled original episode notes and indexed aesthetic interviews, Reddit and podcast leads. October26 DermSurgery Digest is commentary on published studies, not a new controlled readout; full audio and all transcripts were not appraised. No selected new rumor/status change. **Coverage and gaps:** focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; Full source correction/author clarification of IPL efficacy and ethics inconsistencies is outstanding; rare harms and longer durability unestablished.; No verified new trenibotE US decision or exhaustive device-clearance census. **Informal sources and unresolved claims:** Sampled original episode notes and indexed aesthetic interviews, Reddit and podcast leads. October26 DermSurgery Digest is commentary on published studies, not a new controlled readout; full audio and all transcripts were not appraised. No selected new rumor/status change. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28skin+aging+OR+skin+laxity+OR+skin+rejuvenation+OR+wrinkles%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true) - [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28skin+aging+OR+skin+laxity+OR+skin+rejuvenation+OR+wrinkles%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSuf89K3vIFvHRzo5F1yqRaMQNQg) - [Source 3](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT04717934%2CNCT05248867%2CNCT06477172%2CNCT06724900%2CNCT07224880%2CNCT07661004%2CNCT07790237%2CNCT07849205%2CNCT07849556%2CNCT07853027%2CNCT07866131%2CNCT07870694%2CNCT07880756%2CNCT07881926&pageSize=100&format=json) - [Source 4](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22skin+aging%22+OR+%22skin+laxity%22+OR+%22skin+rejuvenation%22+OR+%22wrinkles%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-30%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000) - [Source 5](https://dermsurgerydigest.buzzsprout.com/2364656/episodes/20021371-october-2026-spotlight-cosmetic-and-general-dermatology) - [Source 6](https://link.springer.com/article/10.1007/s10103-026-05082-1) - [Source 7](https://link.springer.com/article/10.1007/s10103-026-05082-1/tables/3) ### Scar prevention, treatment and stretch marks **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** type: fresh registry discovery and all saved NCT refresh; window: 2026-09-05 through 2026-10-30; retrieved: 316; namedIds: NCT02070809; NCT04506255; NCT05461755; NCT06033430; NCT06138964; NCT06944249; NCT07488988; NCT07635875; NCT07849010; NCT07850557; NCT07854470; NCT07868445; NCT07878390; NCT07880860; NCT07891416; errors: ; note: All pages retrieved; selective appraisal only, with older incidental matches excluded.; type: fresh primary MED indexed-paper discovery; window: 2026-09-05 through 2026-10-30; retrieved: 427; note: Core abstracts retrieved, selected full primary sources appraised.; type: primary sponsor/regulator and original informal follow-up; description: Original Syntara index and indexed verteporfin Reddit/talk/podcast leads were checked. Syntara index still leads with October1 scar expansion; no new result selected. DermSurgery Digest October26 notes flag a subcision/suction article, but audio and full primary paper remain unappraised. No new selected rumor/status transition. **Coverage and gaps:** focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; Burn-graft full paper, randomization/attrition, effect sizes and individual harms remain an access gap.; New exosome/subcision NCT07906509 and PRP/insulin/vitaminC NCT07901283 are late registrations of completed studies with no posted results. New thread/plasma-gel NCT07903012 is also retrospectively registered and supplies no result; no proof of superiority. **Informal sources and unresolved claims:** Original Syntara index and indexed verteporfin Reddit/talk/podcast leads were checked. Syntara index still leads with October1 scar expansion; no new result selected. DermSurgery Digest October26 notes flag a subcision/suction article, but audio and full primary paper remain unappraised. No new selected rumor/status transition. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28scar+OR+keloid+OR+stretch+marks%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true) - [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28scar+OR+keloid+OR+stretch+marks%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQuP8-KXvIFvHRzo5F0iyQb8YAT74) - [Source 3](https://clinicaltrials.gov/api/v2/studies?query.term=%28scar+OR+keloid+OR+stretch+marks%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSvfg_K3vIFvHRzo5F0ieZaM4HTr4) - [Source 4](https://clinicaltrials.gov/api/v2/studies?query.term=%28scar+OR+keloid+OR+stretch+marks%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaasfw-LXvIFvHRzo5F0CiXYcEMSb4) - [Source 5](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT02070809%2CNCT04506255%2CNCT05461755%2CNCT06033430%2CNCT06138964%2CNCT06944249%2CNCT07488988%2CNCT07635875%2CNCT07849010%2CNCT07850557%2CNCT07854470%2CNCT07868445%2CNCT07878390%2CNCT07880860%2CNCT07891416&pageSize=100&format=json) - [Source 6](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22scar%22+OR+%22keloid%22+OR+%22stretch+marks%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-30%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000) - [Source 7](https://syntaratx.com.au/news/) - [Source 8](https://dermsurgerydigest.buzzsprout.com/2364656/episodes/20021371-october-2026-spotlight-cosmetic-and-general-dermatology) - [Source 9](https://pubmed.ncbi.nlm.nih.gov/42954344/) - [Source 10](https://doi.org/10.1093/jbcr/irag177) ### Facial volume restoration and contour **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** type: fresh registry discovery and all saved NCT refresh; window: 2026-09-05 through 2026-10-30; retrieved: 165; namedIds: NCT04769193; NCT06351358; NCT07032597; NCT07419854; NCT07805889; NCT07855224; NCT07856797; NCT07877870; NCT07891767; errors: ; note: All pages retrieved; selective appraisal only, with older incidental matches excluded.; type: fresh primary MED indexed-paper discovery; window: 2026-09-05 through 2026-10-30; retrieved: 63; note: Core abstracts retrieved, selected full primary sources appraised.; type: primary sponsor/regulator and original informal follow-up; description: Targeted original Reddit, interview and podcast leads sampled. Removed posts, local clinic availability and self-injection anecdotes do not establish new comparative results or authorized nationwide launch. No noteworthy new development rumor selected. **Coverage and gaps:** focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; RADIESSE secondary GAIS explanatory directions conflict; no results to interpret.; Actual nationwide Belotero launch and complete filler rare-event/long-term surveillance remain unverified. **Informal sources and unresolved claims:** Targeted original Reddit, interview and podcast leads sampled. Removed posts, local clinic availability and self-injection anecdotes do not establish new comparative results or authorized nationwide launch. No noteworthy new development rumor selected. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28dermal+filler+OR+facial+volume+OR+fat+grafting%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true) - [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28dermal+filler+OR+facial+volume+OR+fat+grafting%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSsPw-JXvIFvHRzo5F0CaTbMcNSL4) - [Source 3](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT04769193%2CNCT06351358%2CNCT07032597%2CNCT07419854%2CNCT07805889%2CNCT07855224%2CNCT07856797%2CNCT07877870%2CNCT07891767&pageSize=100&format=json) - [Source 4](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22dermal+filler%22+OR+%22facial+volume%22+OR+%22fat+grafting%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-30%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000) - [Source 5](https://us.merzaesthetics.com/news/) - [Source 6](https://clinicaltrials.gov/study/NCT07856797) ### Pigmentation and uneven skin tone **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** type: fresh registry discovery and all saved NCT refresh; window: 2026-09-05 through 2026-10-30; retrieved: 83; namedIds: NCT03926845; NCT04052425; NCT04057573; NCT06113445; NCT06113471; NCT06118411; NCT07136766; NCT07820098; NCT07840820; NCT07865312; NCT07876323; NCT07881328; NCT07881367; NCT07889492; NCT07896434; errors: ; note: All pages retrieved; selective appraisal only, with older incidental matches excluded.; type: fresh primary MED indexed-paper discovery; window: 2026-09-05 through 2026-10-30; retrieved: 184; note: Core abstracts retrieved, selected full primary sources appraised.; type: primary sponsor/regulator and original informal follow-up; description: Targeted original vitiligo/EB06 and pigmentation Reddit/talk searches sampled. Retrieved EB06 stories repeat the October15 IND announcement already recorded; no new efficacy rumor or confirmed commercial date. Full unindexed comments/audio remain incomplete. **Coverage and gaps:** focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; Crisaborole study late registration and upcoming completion estimates do not establish completed enrollment or readout.; No exhaustive melasma/PIH/lentigines or international vitiligo census; human benefit and safety from every program remain unappraised. **Informal sources and unresolved claims:** Targeted original vitiligo/EB06 and pigmentation Reddit/talk searches sampled. Retrieved EB06 stories repeat the October15 IND announcement already recorded; no new efficacy rumor or confirmed commercial date. Full unindexed comments/audio remain incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28melasma+OR+vitiligo+OR+hyperpigmentation+OR+solar+lentigines%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true) - [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT03926845%2CNCT04052425%2CNCT04057573%2CNCT06113445%2CNCT06113471%2CNCT06118411%2CNCT07136766%2CNCT07820098%2CNCT07840820%2CNCT07865312%2CNCT07876323%2CNCT07881328%2CNCT07881367%2CNCT07889492%2CNCT07896434&pageSize=100&format=json) - [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22melasma%22+OR+%22vitiligo%22+OR+%22hyperpigmentation%22+OR+%22solar+lentigines%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-30%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000) - [Source 4](https://clinicaltrials.gov/study/NCT07904910) ### Acne and rosacea **Coverage: focused/incomplete.** 0 newly recorded entries. **Searches:** type: fresh registry discovery and all saved NCT refresh; window: 2026-09-05 through 2026-10-30; retrieved: 79; namedIds: NCT05296629; NCT05343455; NCT06090721; NCT06248008; NCT06316297; NCT06952517; NCT06989840; NCT07521462; NCT07681271; NCT07805655; NCT07854418; NCT07863193; NCT07866105; NCT07866131; NCT07881315; NCT07883538; errors: ; note: All pages retrieved; selective appraisal only, with older incidental matches excluded.; type: fresh primary MED indexed-paper discovery; window: 2026-09-05 through 2026-10-30; retrieved: 182; note: Core abstracts retrieved, selected full primary sources appraised.; type: primary sponsor/regulator and original informal follow-up; description: Original October7 rosacea recruitment thread was read; its linked Canadian program and speculative psoriasis/pathway comparisons are not efficacy evidence. Indexed patient routine/marketing and podcast leads yielded no selected new development rumor. Full transcripts/comments incomplete. **Coverage and gaps:** focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; Retried October21 CKD/spironolactone PMID42906779: PubMed still has no abstract and Elsevier/JAAD full text remains inaccessible; no numerical result invented.; Full worldwide acne/rosacea program, phenotype-specific harms and antibiotic resistance appraisal remains incomplete; no complete successful check. **Informal sources and unresolved claims:** Original October7 rosacea recruitment thread was read; its linked Canadian program and speculative psoriasis/pathway comparisons are not efficacy evidence. Indexed patient routine/marketing and podcast leads yielded no selected new development rumor. Full transcripts/comments incomplete. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28acne+OR+rosacea+OR+denifanstat+OR+B244%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true) - [Source 2](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT05296629%2CNCT05343455%2CNCT06090721%2CNCT06248008%2CNCT06316297%2CNCT06952517%2CNCT06989840%2CNCT07521462%2CNCT07681271%2CNCT07805655%2CNCT07854418%2CNCT07863193%2CNCT07866105%2CNCT07866131%2CNCT07881315%2CNCT07883538&pageSize=100&format=json) - [Source 3](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22acne%22+OR+%22rosacea%22+OR+%22denifanstat%22+OR+%22B244%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-30%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000) - [Source 4](https://pubmed.ncbi.nlm.nih.gov/42906779/) - [Source 5](https://www.reddit.com/r/Rosacea/comments/1wzikqe/clinical_trial_for_type_2_rosacea_recruiting_now/) ### Dental alignment, regeneration and repair **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** type: fresh registry discovery and all saved NCT refresh; window: 2026-09-05 through 2026-10-30; retrieved: 204; namedIds: NCT02954133; NCT05213338; NCT05361616; NCT06685029; NCT06749977; NCT06881615; NCT07176871; NCT07496892; NCT07638397; NCT07664046; NCT07842120; NCT07859358; NCT07867067; NCT07881146; NCT07883005; NCT07896369; NCT07897864; errors: ; note: All pages retrieved; selective appraisal only, with older incidental matches excluded.; type: fresh primary MED indexed-paper discovery; window: 2026-09-05 through 2026-10-30; retrieved: 496; note: Core abstracts retrieved, selected full primary sources appraised.; type: primary sponsor/regulator and original informal follow-up; description: Original Toregem news index and indexed dental/regeneration podcast/Reddit leads sampled. Latest Toregem announcement remains October20 exhibition news, not dosing. The Richard Miron regenerative-dentistry podcast index was a lead, without full transcript appraisal; no new selected development rumor or verified2030 availability. **Coverage and gaps:** focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; Full enamel-reduction cohort follow-up duration, estimates/intervals and root/gum outcomes remain behind publisher access.; New root-shortening NCT07906951 and bite-raiser NCT07907263 registrations describe completed earlier studies without results; not new2026 efficacy. New MIH restorative studies NCT07906236/NCT07906548 remain protocols.; Full directly printed/shape-memory, remote-monitoring, final bite and retention census incomplete. **Informal sources and unresolved claims:** Original Toregem news index and indexed dental/regeneration podcast/Reddit leads sampled. Latest Toregem announcement remains October20 exhibition news, not dosing. The Richard Miron regenerative-dentistry podcast index was a lead, without full transcript appraisal; no new selected development rumor or verified2030 availability. **Sources checked:** - [Source 1](https://clinicaltrials.gov/api/v2/studies?query.term=%28orthodontic+OR+aligner+OR+tooth+regeneration+OR+enamel+OR+periodontal+regeneration%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true) - [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28orthodontic+OR+aligner+OR+tooth+regeneration+OR+enamel+OR+periodontal+regeneration%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSsPw-JXvIFvHRzo5F0ymUasIETb4) - [Source 3](https://clinicaltrials.gov/api/v2/studies?filter.ids=NCT02954133%2CNCT05213338%2CNCT05361616%2CNCT06685029%2CNCT06749977%2CNCT06881615%2CNCT07176871%2CNCT07496892%2CNCT07638397%2CNCT07664046%2CNCT07842120%2CNCT07859358%2CNCT07867067%2CNCT07881146%2CNCT07883005%2CNCT07896369%2CNCT07897864&pageSize=100&format=json) - [Source 4](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22orthodontic%22+OR+%22aligner%22+OR+%22tooth+regeneration%22+OR+%22enamel%22+OR+%22periodontal+regeneration%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-30%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000) - [Source 5](https://toregem.co.jp/en/news) - [Source 6](https://podfollow.com/on-the-mic-with-map-podcast-mapping-the-way-to-predictable-implant-dentistry/episode/630037bb739f3c8fec62a29da679020d8047d567/view) - [Source 7](https://pubmed.ncbi.nlm.nih.gov/42958839/) - [Source 8](https://doi.org/10.1177/14653125261498917) ### Allergy and airway disease **Coverage: focused/incomplete.** 5 newly recorded entries. **Searches:** 189 phase-limited records and 440 all-phase interventional discovery records retrieved across all pages, saved trials, sponsor fexlamose report and new ARNASA/EPOPEX tables appraised. **Coverage and gaps:** focused_incomplete. No numerical fexlamose effect sizes/harms rates; full ARNASA multiplicity reconciliation, EPOPEX missingness/off-treatment benefit and actual first dosing of newly registered programs remain gaps. Complete worldwide appraisal unfinished. **Informal sources and unresolved claims:** No distinct new original rumor promoted from patient/stock discussion. Two dust-mite registry records share a protocol ID and must not be counted as independent corroborating trials. **Sources checked:** - [Source 1](https://www.globenewswire.com/news-release/2026/10/30/3392177/0/en/aer-therapeutics-announces-top-line-results-from-its-phase-2a-proof-of-concept-trial-of-fexlamose-in-chronic-obstructive-pulmonary-disease-copd.html) - [Source 2](https://clinicaltrials.gov/study/NCT06731959) - [Source 3](https://clinicaltrials.gov/study/NCT05595642) - [Source 4](https://clinicaltrials.gov/study/NCT03859700) - [Source 5](https://clinicaltrials.gov/study/NCT07907991) - [Source 6](https://clinicaltrials.gov/study/NCT07904052) - [Source 7](https://clinicaltrials.gov/study/NCT07904195) - [Source 8](https://clinicaltrials.gov/api/v2/studies?query.term=%28asthma+OR+COPD+OR+%22food+allergy%22+OR+%22chronic+sinusitis%22%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&countTotal=true) - [Source 9](https://clinicaltrials.gov/api/v2/studies?query.term=%28asthma+OR+COPD+OR+%22food+allergy%22+OR+%22chronic+sinusitis%22%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&countTotal=true) ### Infectious-disease prevention and treatment **Coverage: focused/incomplete.** 3 newly recorded entries. **Searches:** 455 phase-limited records, 1,123 all-phase records across12pages, all saved programs, primary ADAPT-Sepsis process paper, new pancoronavirus protocol and updated EMA agenda reviewed selectively. **Coverage and gaps:** focused_incomplete. Hibsago actual commercial access remains unverified. EMA original proceedings/conclusions and INO-3107 FDA action are unverified as of check; today’s target is not an approval. Full antibiotic/phage/antiviral appraisal remains incomplete. **Informal sources and unresolved claims:** Previously recorded AI-phage discussion repeats the same sponsor compassionate-use announcement without patient outcomes. No independent clinical confirmation from reposts. Original podcast/talk coverage remains partial. **Sources checked:** - [Source 1](https://doi.org/10.1111/anae.70439) - [Source 2](https://www.manchesterbrc.nihr.ac.uk/news-and-events/blood-test-could-slash-sepsis-antibiotics/) - [Source 3](https://clinicaltrials.gov/study/NCT07902583) - [Source 4](https://www.ema.europa.eu/en/events/european-medicines-agency-workshop-bacteriophage-therapy) - [Source 5](https://clinicaltrials.gov/api/v2/studies?query.term=%28antibiotic+OR+bacteriophage+OR+vaccine+OR+antiviral%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&countTotal=true) - [Source 6](https://ir.inovio.com/news/) - [Source 7](https://clinicaltrials.gov/api/v2/studies?query.term=%28antibiotic+OR+bacteriophage+OR+vaccine+OR+antiviral%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-30%5D&pageSize=100&format=json&countTotal=true) ### Genetic screening and risk prediction **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** Read current full topic and core notebook files; deduplicated against605 saved events. Search overlap starts September6, through October30, with emphasis on material changes since October27.; Retrieved all pages of the ClinicalTrials.gov topic discovery query (37 records), then142 saved IDs and4 extra trial records in bulk; retrieval is distinct from clinical appraisal.; Focused primary paper, regulator, sponsor, conference and original informal-source searches for genetic_screening; source/event dates retained. **Coverage and gaps:** focused_incomplete. BRIDGES-NBS full paper/supplement not appraised beyond the primary abstract; selection of conditions is not validation.; eMERGE IV patient/provider case-series lead identified, but full outcomes not appraised. No prospective selected-offspring clinical benefit verified.; Worldwide registry, publication and informal-source appraisal remains incomplete; the full-topic successful-check timestamp is unchanged. **Informal sources and unresolved claims:** Previously saved Nucleus/Vitruvian IQ claim remains a model rather than a prospective offspring outcome. PGT-P registry still says not yet recruiting after an October1 estimate. Original X access and broad podcast coverage remain gaps; no repeat alert. **Sources checked:** - [Source 1](https://pubmed.ncbi.nlm.nih.gov/42929308/) - [Source 2](https://clinicaltrials.gov/study/NCT07841769) ### Insomnia **Coverage: focused/incomplete.** 2 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (insomnia OR sleep initiation OR sleep maintenance) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-08-01,2026-10-30]; total: 1784; retrieved: 1784; pages: 18; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeRufk5K3vIFvHRzo5F0CeRasEETL4; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQv_w_K3vIFvHRzo5F0y-ZYcEDQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQvPg4KXvIFvHRzo5F0CyWbsQBTL4; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeQuP8-KXvIFvHRzo5F2SiSYMIBQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeTvf04LXvIFvHRzo5F0CyTb8MDSr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeTuvk4JXvIFvHRzo5F1iqUbsINQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSsPw-JXvIFvHRzo5F0iiWa84HQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSuvQ4KXvIFvHRzo5F0iqZbM4I; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeSuP45L3vIFvHRzo5F2SeWb8AMQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzabvv0_L3vIFvHRzo5F0iiSasYMRr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzabuPU4JXvIFvHRzo5F0CaRacYGSr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaasP85K3vIFvHRzo5F0imUasQHSb4; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaauf44KXvIFvHRzo5F1CeVYMcAQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaVvvw6LXvIFvHRzo5F0iqVbM4AQg; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaVuPQ7K3vIFvHRzo5F0CaWbc8BS74; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaUvfo1L3vIFvHRzo5F0iuQbMcHRr4; https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia+OR+sleep+initiation+OR+sleep+maintenance%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaUuPs8JXvIFvHRzo5F1S-Ra88ASr4; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 insomnia doxepin orexin antagonist daridorexant lemborexant trial results; lemborexant patient reviews October 29 2026 Rutgers Sleep Medicine; site:reddit.com insomnia daridorexant October 2026 trial **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; Recovered online-review research is self-selected, not a controlled incidence estimate or new FDA safety action.; Insomnia registry terms yield many incidental/perioperative records; complete screening and human-device/digital-therapy safety appraisal remain incomplete.; Perioperative lemborexant wearable total sleep time does not establish polysomnographic architecture or durable insomnia remission. **Informal sources and unresolved claims:** Re-read the existing ENLIGHTEN-6 and TAK-360 original experience threads that overlap insomnia. Symptoms remain unverified individual accounts. The lemborexant online-review paper is a formal analysis of self-selected reports, not an independent confirmation of those trial anecdotes. **Sources checked:** - [Source 1](https://clinicaltrials.gov/study/NCT07903038) - [Source 2](https://clinicaltrials.gov/study/NCT07903051) - [Source 3](https://pubmed.ncbi.nlm.nih.gov/42822395/) - [Source 4](https://www.rutgers.edu/news/why-some-patients-quit-newer-insomnia-medication) ### Obstructive sleep apnea **Coverage: focused/incomplete.** 0 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (obstructive sleep apnea) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-08-01,2026-10-30]; total: 144; retrieved: 144; pages: 2; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28obstructive+sleep+apnea%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://clinicaltrials.gov/api/v2/studies?query.term=%28obstructive+sleep+apnea%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaau_07L3vIFvHRzo5F0i6Qa8QBRr4; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: AD109 CHEST 2026 original menopause hypoxic burden tables; retatrutide obstructive sleep apnea NEJMoa2611477 supplement; site:reddit.com October 2026 AD109 trial **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; Retatrutide OSA full NEJM article/supplement again returned 403 on October 30; detailed arm-specific GI/discontinuation denominators remain a gap.; AD109 CHEST original menopause, hypoxic-burden/BP and per-protocol patient-reported-outcome tables remain unavailable. Original investigator interview was re-read, but its exploratory results are not substituted for the original tables.; Complete long-term PAP/device comparative harms, clinical cardiovascular outcomes and non-U.S. OSA coverage remain incomplete. **Informal sources and unresolved claims:** Re-read Reena Mehra’s original October 22 HCPLive interview and its explicit post hoc/hypothesis-generating limitations. The underlying CHEST tables remain missing. Targeted AD109 Reddit searches did not provide independent confirmatory evidence. **Sources checked:** - [Source 1](https://pubmed.ncbi.nlm.nih.gov/42904878/) - [Source 2](https://www.hcplive.com/view/ad109-greater-osa-improvements-postmenopausal-women) ### Narcolepsy & excessive sleepiness **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (narcolepsy OR idiopathic hypersomnia OR orexin agonist) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-08-01,2026-10-30]; total: 27; retrieved: 27; pages: 1; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28narcolepsy+OR+idiopathic+hypersomnia+OR+orexin+agonist%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 oveporexton DEA scheduling TAK360 orexin alixorexton; Sleep Europe 2026 alixorexton long term extension abstract original; site:reddit.com/r/Narcolepsy October 2026 orexin trial **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; Actual DEA scheduling/commercial availability was not verified for oveporexton; no launch date inferred from approval or an old proposed schedule.; Original alixorexton abstract was recovered, but complete extension visit/arm uncertainty and harms tables remain unavailable; extension groups do not preserve randomized allocation. **Informal sources and unresolved claims:** Re-read the original TAK-360 Reddit discussion, including u/statistics_squirrel’s nighttime-fragmentation account. Exact dose, assignment, causality and source date remain unknown. New orexin-community searches were selective and did not provide a meaningful status change. **Sources checked:** - [Source 1](https://onlinelibrary.wiley.com/doi/full/10.1111/jsr.70459) - [Source 2](https://www.alkermesmedicalaffairs.com/pdf?file=%2Fresources%2Fcongresses%2Fesrs-2026%2Fphase-2-and-long-term-extension-results-from-treatment-with-the-orexin-2-receptor-agonist-alixorexton-demonstrated-clinically-meaningful-improvements-in-symptoms-of-narcolepsy-type-1-and-2%2Fposter-pdf) - [Source 3](https://clinicaltrials.gov/study/NCT06767683) ### Circadian rhythm disorders **Coverage: focused/incomplete.** 0 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (circadian OR delayed sleep wake OR shift work disorder) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-08-01,2026-10-30]; total: 353; retrieved: 353; pages: 4; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28circadian+OR+delayed+sleep+wake+OR+shift+work+disorder%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://clinicaltrials.gov/api/v2/studies?query.term=%28circadian+OR+delayed+sleep+wake+OR+shift+work+disorder%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzeTsPk1K3vIFvHRzo5F0iqZYMIHTL4; https://clinicaltrials.gov/api/v2/studies?query.term=%28circadian+OR+delayed+sleep+wake+OR+shift+work+disorder%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzabvv0_L3vIFvHRzo5F0iiRb8AMTb4; https://clinicaltrials.gov/api/v2/studies?query.term=%28circadian+OR+delayed+sleep+wake+OR+shift+work+disorder%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true&pageToken=ZVJ76sWHmqU2wRk2CJf6_LLvzZHcI8Brd7KrgP4bmzaVuPw9L3vIFvHRzo5F1yyUbsQAQg; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 circadian DSPD Non24 tasimelteon shift work SmartEnLite clinical trial; site:reddit.com October 2026 circadian tasimelteon trial **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; No new efficacy result was selected in the sources appraised; the baseline and worldwide shift-work/DSPD/Non24 harms review remain incomplete.; SmartEnLite retains its December 1 estimated start and February 2031 estimated primary completion; neither is a result or proof of disease modification. Current tasimelteon docket outcome was not independently resolved. **Informal sources and unresolved claims:** Targeted original Reddit searches concerning circadian treatment, tasimelteon and shift work were reviewed selectively. No new attributed trial-development claim was selected; this is incomplete informal coverage, not a claim that no rumors exist. **Sources checked:** - [Source 1](https://clinicaltrials.gov/study/NCT07883291) ### Restless legs syndrome **Coverage: focused/incomplete.** 1 newly recorded entries. **Searches:** type: ClinicalTrials.gov paginated discovery; query: (restless legs syndrome) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-08-01,2026-10-30]; total: 13; retrieved: 13; pages: 1; allPagesRetrieved: True; errors: ; urls: https://clinicaltrials.gov/api/v2/studies?query.term=%28restless+legs+syndrome%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-08-01%2C2026-10-30%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; type: Named record refresh; combinedNamedRecordsRetrieved: 147; combinedNamedErrors: ; note: Named records across the ten assigned topics; not 147 unique records within this one topic.; type: Targeted primary and original informal searches; queries: October 2026 restless legs TOMAC Nidra CT10 augmentation trial results; randomized local vibration gabapentin restless legs 2026; site:reddit.com October 2026 Nidra trial **Coverage and gaps:** Focused partial appraisal through October 30, 2026. Complete retrieval of the specified query and saved named records; incomplete worldwide review. No full successful-check or baseline-completion claim.. Focused appraisal only. All pages of the specified ClinicalTrials.gov query were retrieved, but not every returned record underwent full results/harms appraisal. This is not complete worldwide coverage.; Independent non-U.S. registry searches, a comprehensive publication/hold/discontinuation census, and complete original conference/podcast audio and transcripts remain incomplete. Full successful-check timestamps and incomplete sleep baseline flags must remain unchanged.; CT10 remains not yet recruiting in the retrieved February 9 record despite its elapsed April estimated start; actual initiation is unverified.; Complete 2026 RLS algorithm, iron/medicine/device harms and long-term augmentation/functional-outcome comparison remain incomplete; no efficacy inferred from anecdotes. **Informal sources and unresolved claims:** Targeted original Reddit searches on TOMAC/Nidra and RLS trials were selective. Individual experiences were not used as comparative efficacy or regulatory confirmation; complete informal-source coverage remains incomplete. **Sources checked:** - [Source 1](https://pubmed.ncbi.nlm.nih.gov/42908006/) - [Source 2](https://pmc.ncbi.nlm.nih.gov/articles/PMC13688849/) - [Source 3](https://clinicaltrials.gov/study/NCT07397247) ## Homepage and publication The homepage rotates from EloraTZP to the new October 28 TRANSCEND-T2D-2 sponsor head-to-head report. Matching 12 mg retatrutide/2 mg semaglutide efficacy and adverse-event discontinuation rates are shown together, with the actual 80-week duration, modeled efficacy estimand and sponsor-only limitations. The 9 mg nominal versus 12 mg controlled A1c comparisons remain distinct. Historical curves and endpoints are retained; new diabetes weight estimates are not placed on the non-diabetic endpoint map or invented into curves. The public projection excludes personal context and retains exact evidence passages. Release validators and native deployment status verify this background publication; no browser QA is claimed. The publication receipt is written privately after successful deployment. If publication fails, the canonical notebook remains current and the website is marked stale.